Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer

Abstract

Breast cancer is a highly heterogeneous group of diseases posing a significant challenge in biomarker-driven research and the development of effective targeted therapies. Especially the treatment of metastatic breast cancer poses even more challenges, as we still lose more than 42,000 women and men each year in the United States alone. New biological insight helps to improve breast cancer treatment through early detection, adaptation to chemotherapy resistance, and tailoring to find the right size of care. This review focuses on existing and new areas of predictive biomarkers under development to tailor the management of breast cancer and the application of integrative approaches that have resulted in the promising candidate biomarker discovery. Furthermore, we review new methods to detect metastatic progression using imaging, and blood-based assays. We hope to increase the attention and awareness of a new generation of therapeutic development strategies in metastatic breast cancer.

Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance

“…For instance, in conditions of glutamine deficiency tumor cells use asparagine instead to sustain migration [ 88 , 89 ]. In addition, systemic therapy, by imposing a challenging environment, can force cancer cells to adapt their metabolic pathways to lipid metabolism [ 90 ].…”

In Vitro and In Vivo Preventive Effects of Thymoquinone against Breast Cancer: Role of DNMT1

“…Breast cancer (BC) is a complex disease characterized by distinct biological subtypes and numerous targeted prognostic markers of therapeutic importance [ 1 , 2 ]. In 2012, 1.7 million BC cases and 521,900 deaths were reported [ 3 ].…”

Design, synthesis, molecular docking and in vitro anticancer activities of 1-(4-(benzamido)phenyl)-3-arylurea derivatives

“…The most common type of cancer among women is breast cancer (BC), globally. 6 BC is a highly complex disease with distinct biological subtypes and several targeted prognostic markers of therapeutic significance. 7 Approximately 2.3 million (11.7%) new instances of breast cancer were reported in 2020, and 684 996 (6.9%) fatalities were linked to the disease.…”

“… 6 BC is a highly complex disease with distinct biological subtypes and several targeted prognostic markers of therapeutic significance. 7 Approximately 2.3 million (11.7%) new instances of breast cancer were reported in 2020, and 684 996 (6.9%) fatalities were linked to the disease. 1 Furthermore, It is predicted that by 2040, there will be around 3 million new cases of breast cancer and one million more deaths from the disease.…”